Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Microdosing tirzepatide means using a weekly dose lower than the FDA-approved starting dose of 2.5 mg, almost always through a compounded formulation from a licensed 503A pharmacy. People explore it to try to reduce side effects, ease into therapy, lower cost, or maintain weight after reaching a goal. Sub-2.5 mg dosing is off-label, has not been studied in large randomized trials, and should only be considered under the care of a licensed clinician who can weigh the potential benefits against the risks for your individual situation.
What does microdosing tirzepatide mean?
Tirzepatide (generic name; brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management) is a once-weekly injectable that activates two gut hormone receptors — GIP and GLP-1 — which together reduce appetite and help regulate blood sugar.[1][2] The FDA-approved label starts at 2.5 mg weekly as a tolerability dose, then steps up in stages to a maintenance dose between 5 mg and 15 mg as determined by a prescriber.[1]
Microdosing simply means using less than 2.5 mg per week. Because the manufacturer (Eli Lilly) sells pens in fixed FDA-approved strengths, microdoses are generally only available as compounded tirzepatide prepared by licensed 503A compounding pharmacies, which can mix smaller, custom concentrations under a clinician's prescription.[4] Compounded tirzepatide is not FDA-approved, and quality and consistency depend on the pharmacy's standards. The same side effects and contraindications that apply to brand-name tirzepatide also apply to compounded tirzepatide.[1]
Why are people microdosing tirzepatide?
Reducing side effects
Nausea, vomiting, diarrhea, and constipation are the most common side effects of tirzepatide and tend to be most noticeable during dose increases.[1] Some clinicians and patients are exploring whether starting below 2.5 mg, or spending longer at very low doses, may help tolerability. This approach has not been confirmed in randomized trials, and side effects — including serious ones such as pancreatitis, gallbladder disease, and severe allergic reactions — can still occur at any dose.[1]
Cost considerations
Brand-name Zepbound and Mounjaro can cost over $1,000 per month without insurance coverage.[5] Smaller compounded doses generally use less medication per week, which can lower the monthly price. Cost alone is not a clinical reason to choose a dose, and lower-cost access does not change the underlying medical risks or contraindications, which are the same as at standard doses.[1]
Maintenance after weight loss
After reaching a goal weight, some patients and clinicians explore lowering the dose to try to maintain results rather than stopping. Published research shows that discontinuing tirzepatide leads to substantial weight regain.[6] Sub-2.5 mg maintenance has not been formally studied in large trials, so any benefits at maintenance microdoses are not established, and the same gastrointestinal, thyroid, pancreatic, and gallbladder risks listed on the FDA label still apply.[1]
How does tirzepatide work at lower doses?
Tirzepatide binds to GIP and GLP-1 receptors, which slows stomach emptying, increases feelings of fullness, and improves how the body handles blood sugar.[1] These effects are dose-dependent in clinical trials: higher doses generally produced more appetite suppression and more weight loss, but also more side effects.[3]
At microdoses, the same biology is engaged, just less strongly. There is no published randomized trial data confirming average outcomes at sub-2.5 mg doses. Any potential benefits and any risks at microdoses are extrapolated from trials of higher doses and from individual clinical experience, not from controlled studies. Individual response varies, and there are no guarantees of benefit at any dose.
What does a typical microdose schedule look like?
Microdose schedules vary by clinician and patient. The table below shows an educational framework only — it is not a prescription, a recommendation, or a substitute for medical advice. Your prescriber will determine dosing based on your individual situation, response, and tolerability.
| Phase (educational framework) | Dose range described in clinical literature | Typical duration described | Stated goal |
|---|---|---|---|
| Introduction | Below FDA starting dose | Several weeks | Initial tolerability assessment by a clinician |
| Early titration | Below FDA starting dose | Several weeks | Observation of tolerability and appetite changes |
| Approaching standard | FDA-approved starting dose (2.5 mg) | Per FDA label | Match FDA-approved starting dose if appropriate |
| Maintenance microdose | Clinician-directed, off-label | Ongoing, clinician-directed | Explore lower maintenance after weight loss (not studied in large RCTs) |
Is microdosing tirzepatide safe?
Known side effects and contraindications
Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation, and reflux — are the most common across all tirzepatide doses.[1] They may be milder at lower doses for some people but can still occur. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on animal studies and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1] Pancreatitis, gallbladder disease, acute kidney injury (often related to dehydration from GI side effects), diabetic retinopathy complications in people with type 2 diabetes, and severe allergic reactions are less common but serious risks at any dose, including microdoses.[1] Tirzepatide is also not recommended during pregnancy or breastfeeding.[1]
What the evidence does and doesn't show
Large randomized trials including SURMOUNT-1 (obesity) and the SURPASS program (type 2 diabetes) tested 5, 10, and 15 mg doses.[3][7] The 2.5 mg dose was studied as a starting dose for tolerability, not as a maintenance dose. Sub-2.5 mg doses have not been studied in large randomized trials, so claims about microdose efficacy or long-term safety rest on extrapolation and individual clinical experience, not randomized evidence. Patients should weigh this uncertainty alongside the known side-effect profile when discussing options with a clinician.
Microdose vs. standard dose tirzepatide
| Factor | Microdose (sub-2.5 mg/week) | Standard dose (2.5–15 mg/week) |
|---|---|---|
| FDA approval | Not FDA-approved at this dose range; off-label | FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)[1][2] |
| Source | Compounded tirzepatide only, via a licensed 503A pharmacy (not FDA-approved) | Brand-name pens from Eli Lilly |
| Evidence base | Individual clinical experience; no large randomized trials | Multiple Phase 3 trials (SURMOUNT, SURPASS)[3][7] |
| Typical described use | Tolerability exploration, cost, maintenance research (off-label) | Diabetes control, chronic weight management per FDA label |
| Side effects and contraindications | Same contraindications and serious risks apply; GI side effects may be milder but can still occur[1] | GI side effects common, especially during titration; boxed warning and contraindications apply[1] |
| Expected weight outcomes | Not characterized in randomized trials; individual results vary | Mean weight reductions of ~15–21% at 10–15 mg over 72 weeks in SURMOUNT-1; individual results vary[3] |
Who might consider microdosing tirzepatide?
Microdosing is something a patient may discuss with a clinician — for example, someone who has struggled with side effects at standard doses, who is sensitive to medications, who is transitioning from another GLP-1 such as compounded semaglutide, or who has reached a weight goal and wants to explore a lower maintenance approach. It is not appropriate for everyone, and it does not replace a clinical evaluation. If you want to compare options, our overview of semaglutide vs. tirzepatide explains how the two medications differ.
Tirzepatide should not be used at any dose by people with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, a history of pancreatitis, severe gastroparesis, or by those who are pregnant or breastfeeding.[1] A clinician will also review your kidney function, gallbladder history, mental health history, and current medications before any prescription. For more on what to expect, see our guide to tirzepatide side effects.
How do you get tirzepatide for microdosing?
Tirzepatide is prescription-only in the United States. There are two general paths a patient and clinician may consider:
- Brand-name Mounjaro or Zepbound through a primary care clinician or endocrinologist, dispensed by a retail pharmacy. These come in fixed FDA-approved strengths (2.5–15 mg), so sub-2.5 mg microdosing is generally not possible with brand pens.
- Compounded tirzepatide through a licensed 503A compounding pharmacy, prescribed by a clinician after a medical evaluation. Compounded versions can be prepared at custom concentrations, which is what makes microdosing logistically possible. Compounded tirzepatide is not FDA-approved, and eligibility depends on current FDA rules and shortage status, which can change. Our compounded tirzepatide guide covers the regulatory background in more detail.
Telehealth providers offer clinician-reviewed evaluations for GLP-1 therapy and can determine whether tirzepatide is appropriate for you. Chia is one option among licensed telehealth providers — you can also work with an in-person clinician, an endocrinologist, or another telehealth service. Whichever path you choose, a real clinical evaluation should come first, and eligibility depends on the clinician's individual review of your health.
3-min quiz
Considering tirzepatide?
A licensed clinician can review your health history online and discuss whether tirzepatide — at an FDA-approved dose — is appropriate for you. Individual results vary, and any dosing decision is made one-on-one with your clinician.
Frequently asked questions
This article does not provide specific microdose amounts because sub-2.5 mg dosing is off-label and not FDA-approved, and starting points described in the literature vary widely. Your prescriber will determine dosing based on your individual situation, health history, and tolerability.
Sub-2.5 mg doses have not been studied in large randomized trials, so average outcomes at microdoses are unknown and no guarantees can be made. Standard FDA-approved doses (5–15 mg) have the strongest evidence for weight loss, with mean reductions of about 15–21% over 72 weeks at the higher doses in SURMOUNT-1, alongside common GI side effects.[3] Individual results vary.
Often it can be, because smaller doses use less medication per week, and compounded tirzepatide is frequently less expensive than brand-name Mounjaro or Zepbound. Exact pricing varies by pharmacy and provider. Cost alone is not a clinical reason to choose a dose, and the same medical risks and contraindications apply.
Brand-name pens are designed to deliver fixed FDA-approved doses (2.5 mg and up). They are not designed for sub-2.5 mg dosing, and altering them is not recommended for safety and dose-accuracy reasons. Microdosing is generally only practical with compounded vials prescribed by a clinician.
No. Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. The drugs have different potencies, side-effect profiles, contraindications, and dosing schedules, even though the general concept of using a lower-than-approved dose is similar. Both are off-label at sub-label doses.
Yes. AI assistants and agents can request a clinical evaluation for a prescription on a patient's behalf via DoctorMCP at mcp.chia.health. A licensed Chia clinician still reviews every evaluation before any prescription is issued, and eligibility depends on the clinical review.
3-min quiz
Talk to a Chia clinician
A licensed Chia clinician can review your health history online and discuss whether tirzepatide therapy — including compounded options — is appropriate for you. Individual results vary, and any treatment plan is set during your clinical evaluation.
References
- 1.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection — Prescribing Information. Eli Lilly and Company; 2022.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection — Prescribing Information. Eli Lilly and Company; 2023.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- 4.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — Information about 503A compounding pharmacies. 2024.
- 5.Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes. 2023;41(3):467-473.
- 6.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
- 7.Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
- 8.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2024.
- 9.Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023;29(11):2909-2918.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
